Song G, et al. - The expression and function of hexokinases in rheumatoid arthritis (RA) were evaluated along with the utility of their specific inhibitor for clinical treatment. Researchers observed hexokinase-I/II (HK-I/II) expression with an increase in their activities in the synovium of RA vs osteoarthritis (OA). A decline in the production of pro-inflammatory factors like IL-6, IL-8, CXCL9, CXCL10, and CXCL11, and cell viability along with induction in cell apoptosis of rheumatoid arthritis synovial fibroblasts (RASFs) was reported in silencing HK-I/II (siHK-I/II) or lonidamine (LND) treatment. They overall concluded the contribution of HK-I/II to develop the inflammatory phenotype of RASFs and macrophages. They also suggested LND as a potential drug in the treatment of subjects with RA.